AskBio reveals the enrollment of their initial patient into the Phase 1 trial for AB-1005 (AAV2-GDNF), their gene therapy solution to Multiple System Atrophy-Parkinsonian Type (MSA-P).

Medicenna reports promising survival gains from the Phase 2b trial of Bizaxofusp for relapsed Glioblastoma, revealed at the 28th yearly NeuroOncology Society gathering.

EBGLYSS® (lebrikizumab), developed by Almirall, has been given the green light by the European Commission for the treatment of moderate-to-severe atopic dermatitis.

US approval granted for combination of Truqap (capivasertib) and Faslodex for treating advanced HR-positive breast cancer patients.

Polaris Group commences phased submission of a BLA for ADI-PEG 20 to the U.S. FDA to manage Malignant Pleural Mesothelioma.

Astellas and Pfizer's XTANDI® gets FDA approval for update, following fast-tracked review and EMBARK study results.

Q32 Bio, a biotech company in clinical phase, is regaining full rights for bempikibart (formerly ADX-914) from Amgen to focus on developing immune-balancing biologic therapies.

argenx reveals green light from European Commission for the subcutaneous usage of VYVGART® (efgartigimod alfa) in treating Generalized Myasthenia Gravis.

The first patient was treated with ALE.C04 in a Phase 1/2 study by Alentis Therapeutics, aimed at treating Head and Neck Squamous Cell Carcinoma (HNSCC).

CRISPR Therapeutics and Vertex received approval from the UK's MHRA for the initial gene-edited treatment, CASGEVY™ (exagamglogene autotemcel), targeting Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia employing CRISPR/Cas9 technology.

Carmot Therapeutics has initiated a phase 2 clinical study on CT-868, a unique dual GLP-1/GIP receptor agonist, to treat Type 1 Diabetes.

Repare Therapeutics introduces two initiatives set to commence clinical testing by 2024: oral PLK4 inhibitor RP-1664, and oral Polθ inhibitor RP-3467.